Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban in heparin-induced thrombocytopenia
IRCT20200325046854N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of apixaban in heparin-induced thrombocytopenia (HIT), sponsored by Iran University of Medical Sciences. Started May 2021; status: completed.
02
Drugs
apixaban
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on IRCT20200325046854N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200325046854N1.